Myelofibrosis Treatment in India
- Top Accredited Hospitals
- Global Medical Standards
- Cutting-Edge Technology
- Proven Treatment Options
- High Success Rate
- Trusted by Millions
What is Myelofibrosis?
Myelofibrosis is a chronic blood cancer and myeloproliferative neoplasm in which abnormal blood-forming cells and changes in the bone marrow environment cause progressive bone marrow fibrosis. As normal blood-cell production becomes impaired, patients may develop anemia, low platelet counts or abnormal white blood-cell counts. The spleen and liver may begin producing blood cells outside the bone marrow, which can enlarge these organs. Myelofibrosis may develop on its own as primary myelofibrosis or occur after another myeloproliferative neoplasm such as polycythemia vera or essential thrombocythemia.
What is the Importance of Timely Treatment?
Timely diagnosis and risk assessment are important because myelofibrosis can progress differently from one person to another. Some patients have stable disease and require regular monitoring, while others develop significant anemia, thrombocytopenia, symptomatic splenomegaly, constitutional symptoms or progression to an advanced phase of disease. Early specialist assessment helps determine disease risk, monitor blood counts and symptoms, manage complications and identify patients who may be candidates for potentially disease-modifying treatment such as allogeneic stem-cell transplantation.
What are the Common Symptoms of Myelofibrosis?
- Persistent fatigue and weakness
- Shortness of breath, particularly with activity
- Pale skin due to anemia
- Unexplained weight loss
- Fever or night sweats
- Loss of appetite
- Bone or muscle pain
- Abdominal fullness or discomfort due to an enlarged spleen
- Feeling full after eating a small amount
- Easy bruising or bleeding
- Frequent infections in some patients
- Itching
- Reduced exercise tolerance
Causes and Risk Factors of Myelofibrosis
Causes
- Myelofibrosis develops when abnormal blood-forming stem or progenitor cells acquire genetic changes that promote uncontrolled or abnormal blood-cell production and release inflammatory signals that alter the bone marrow environment.
- Mutations involving genes such as JAK2, CALR and MPL are commonly associated with myelofibrosis, although some patients do not have any of these driver mutations.
- Primary myelofibrosis develops independently, while secondary myelofibrosis can develop after polycythemia vera or essential thrombocythemia.
Risk Factors
- Increasing age
- Presence of an underlying myeloproliferative neoplasm such as polycythemia vera or essential thrombocythemia
- Certain acquired genetic mutations
- Previous treatment or disease-related factors associated with secondary myelofibrosis
- Certain adverse molecular or cytogenetic features associated with higher-risk disease
Latest Research and Technologies in the Treatment of Myelofibrosis in India
- Current myelofibrosis research is focused on improving symptom and spleen control, treating anemia and developing therapies that may alter disease progression. JAK inhibitors remain an important targeted treatment approach, while newer and investigational therapies are being studied for patients with anemia, thrombocytopenia, inadequate response or intolerance to existing treatments. Clinical research is also evaluating combinations of targeted therapies and approaches involving JAK inhibitors around allogeneic hematopoietic stem-cell transplantation.
Treatment options for Myelofibrosis
Stem-Cell Transplantation : Allogeneic hematopoietic stem-cell transplantation is a potentially disease-modifying treatment and may be considered for selected patients with higher-risk disease who are medically suitable for transplantation. Pre-transplant disease control and donor selection are important parts of treatment planning.
Cost Start From 11500Explore Options
- Clinical assessment:
- Medical and Hematological Evaluation: A detailed history is taken to assess fatigue, weight loss, fever, night sweats, abdominal discomfort, bleeding, infections, bone pain and other constitutional symptoms. The physician also reviews previous blood disorders, treatment history, medications and family history.
- Complete Blood Count and Peripheral Blood Assessment: A peripheral blood smear may show characteristic abnormalities such as immature blood cells or tear-drop-shaped red blood cells and can provide additional information about abnormal blood-cell production.
- Bone Marrow Evaluation: Bone marrow aspiration and biopsy are central to diagnosing myelofibrosis. The biopsy evaluates the degree and pattern of bone marrow fibrosis, abnormal megakaryocytes and other marrow changes. It also helps distinguish myelofibrosis from other myeloid disorders.
- Molecular and Cytogenetic Assessment: Cytogenetic testing can identify chromosomal abnormalities and may contribute to risk assessment.
- Risk and Prognostic Assessment: Doctors assess clinical, laboratory, cytogenetic and molecular features to estimate disease risk and guide treatment decisions.
- Imaging Tests:
- Abdominal Ultrasound: Helps assess spleen and liver size and can be useful for monitoring splenomegaly.
- CT Scan: Provides more detailed assessment of the spleen, liver, lymph nodes and abdominal structures when required.
- MRI: May be used selectively to evaluate bone marrow or other areas when additional structural information is needed.
- PET/CT: May be considered in selected situations when extramedullary disease or another complication requires further evaluation.
- Imaging for Treatment Monitoring: Ultrasound or CT may be used to monitor changes in spleen size during treatment.
MediRehab (a chain of Rehab centres, part of MediGence) provides comprehensive rehabilitation services designed to support Myelofibrosis patients in India. These services include:
- Physical Activity and Exercise: Individually tailored physical activity can help maintain muscle strength, endurance and mobility, with intensity adjusted according to anemia, platelet levels, fatigue and overall health.
- Nutritional Support: Dietitians can provide personalised nutrition guidance to support adequate calorie and protein intake, manage appetite loss and address nutritional deficiencies or treatment-related needs.
- Fatigue Management: Structured activity planning, adequate rest, energy-conservation techniques and treatment of underlying anemia can help patients manage persistent fatigue.
- Functional Rehabilitation: Patients with weakness, reduced exercise tolerance, pain or prolonged hospitalisation may benefit from physiotherapy and occupational therapy to maintain independence.
- Psychological and Long-Term Support: Counselling, patient education and support programmes can help patients cope with a chronic blood cancer, treatment-related stress and the need for long-term monitoring or transplantation.
- Medicines for myelofibrosis are selected according to symptoms, spleen enlargement, anemia, platelet counts, disease risk and previous treatment. JAK inhibitors may be used to reduce disease-related symptoms and splenomegaly in appropriate patients. Treatment of anemia may include red-blood-cell transfusions, erythropoiesis-supporting medicines or other selected therapies depending on the underlying cause and clinical circumstances. Additional medicines may be used to manage infections, bleeding, pain, constitutional symptoms or other complications.
Instantly Connect with our Specialists
Hospitals for Myelofibrosis in India
Artemis Health Institute
Gurgaon, India
Artemis Hospital, established in 2007 in Gurgaon, India, is a 750+ bed, state-of-the-art multi-speciality hospital and the first in Gurgaon accredited by JCI and NABH. A flagship of the Apollo Tyres Group, it offers advanced care across cardiology, oncology, orthopaedics, neurology, and transplant medicine, supported by modern infrastructure and 60+ world-class operating theatres. Its Centres of Excellence span critical areas like heart, cancer, neurosciences, orthopaedics, and women & child care. Guided by values of Service, Compassion, and Integrity, Artemis combines innovation, technology, and affordability, making it a trusted international healthcare destination for comprehensive and compassionate patient care.
Venkateshwar Hospital
Delhi, India
Venkateshwar Hospital located in New Delhi, India is accredited by NABH. Also listed below are some of the most prominent infrastructural details:
- The hospital has the latest healthcare facilities and world class infrastructure.
- It has a 325 bed capacity and 100 beds for critical care.
- There are as many as 10 operation theatres.
- The Intensive Care Unit and blood bank is also present within the hospital.
- There is complete support for international patients with facilities such as transfers, assistance for visa and accommodation, translators and insurance related assistance.
- Some of the departments in which medical services are available are Plastic and Reconstructive Surgery, Orthopedics, Gynecology, Cardiology, Neurology and Oncology.
- The hospital also provides treatment for infertility, weight loss and has physiotherapy and pain management services.
Marengo Asia Hospitals, Faridabad
Faridabad, India
Marengo Asia Hospitals, located in Faridabad, is a multispecialty, state-of-the-art, and patient-friendly facility that combines the greatest services available in the healthcare segment. With 325 beds now, the hospital can accommodate up to 550 beds. It has first-rate medical facilities including a Critical Care Medicine department for patients with life-threatening conditions. Furthermore, our highly skilled medical staff and cutting-edge software system make us the perfect facility for patients from various backgrounds. We always aim to exceed expectations and are always looking for ways to boost our performance.
Our Services to better your experience
Opinion & Option
We submit the most accurate opinion and options from one or more countries for your review
Consult Privately
Consult with a certified specialist privately on our telemedicine platform even before you decide to travel
Logistics
We handle flights, visas, transfers, and accommodation—so you can focus on your health.
Recovery
Our In-house rehabilitation service packages to better your recovery and treatment outcome
Why Choose India for Myelofibrosis Treatment?
- Multidisciplinary Hematology Care: Patients can access hematologists, hemato-oncologists, transfusion specialists, transplant physicians and supportive-care teams according to their clinical needs.
- Advanced Diagnostic Facilities: Specialised centres may provide bone marrow biopsy, molecular testing for myelofibrosis-associated mutations, cytogenetic analysis and advanced imaging.
- Targeted Treatment Options: Eligible patients may receive modern JAK-inhibitor therapy and supportive treatments based on disease characteristics and blood counts.
- Stem-Cell Transplantation: Major transplant centres can evaluate suitable patients for allogeneic hematopoietic stem-cell transplantation, including donor assessment and post-transplant monitoring.
- Comprehensive Support and International Patient Services: Blood transfusion support, nutritional counselling, rehabilitation, follow-up care and international-patient coordination can be incorporated into the treatment pathway.